Docosahexaenoic Acid (DHA) Effects on Cognitive Function, Craving and Psychosocial Factors in Heavy Cigarette Smokers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01284660 |
Recruitment Status
:
Completed
First Posted
: January 27, 2011
Last Update Posted
: December 19, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HEAVY TOBACCO SMOKERS | Dietary Supplement: DHA Dietary Supplement: Oral ingestion of 5 placebo tablets | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 51 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Supportive Care |
Study Start Date : | November 2011 |
Actual Primary Completion Date : | July 2013 |
Actual Study Completion Date : | September 2013 |
Arm | Intervention/treatment |
---|---|
Active Comparator: I. DHA
Oral ingestion 5 tablets DHA + EPA (daily ingestion DHA 2040 mg and EPA 2710 mg)- (Omega 3 - 950,the Solgar Pharmaceutical Co., Israel).
|
Dietary Supplement: DHA
DHA ingested orally by heavy smokers
|
Placebo Comparator: II. Placebo
Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
|
Dietary Supplement: Oral ingestion of 5 placebo tablets
Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
|
- Reduction in smoking urges and craving [ Time Frame: One and a half years ]Reduction in smoking urges and craving to be measured by the following: smoking urges and craving scales; choice reaction time, impulsivity computerized test, quality of life questionnaire, depression inventory, general health questionnaire, scale of perceived social support, facial expression task, self-esteem diary

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Nicotine dependence
- Smoked at least 10 cigarettes per day for the past 12 months and not interested in quitting
Exclusion Criteria:
- Serious kidney, lun, neurological and cardiovascular diseases
- Suicide risk, acute psychosis, severe depression, organic brain syndromes
- Dependence on psychoactive substances other than nicotine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01284660
Israel | |
Bar Ilan University | |
Ramat Gan, Israel, 52900 |
Responsible Party: | Hillel Yaffe Medical Center |
ClinicalTrials.gov Identifier: | NCT01284660 History of Changes |
Other Study ID Numbers: |
00009-11 HYMC |
First Posted: | January 27, 2011 Key Record Dates |
Last Update Posted: | December 19, 2013 |
Last Verified: | December 2013 |